Tech Company Financing Transactions

Immune Control Funding Round

Immune Control, based in West Conshohocken, secured $11.3 million from Anthem Capital, BioAdvance Ventures and Domain Associates.

Transaction Overview

Company Name
Announced On
7/14/2005
Transaction Type
Venture Equity
Amount
$11,300,000
Round
Series A
Investors

Anthem Capital (Lead Investor) (Gerry Schaafsma)

BioAdvance Ventures

Domain Associates (Brian Halak)

NewSpring Capital (Zev Scherl)

Quaker Partners

Proceeds Purpose
The Series A investment will fund the development and initial clinical trial of serotonin antagonists as treatments for diseases marked by aberrant immune activation.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
200 Barr Harbor Drive 450
West Conshohocken, PA 19428
USA
Email Address
Overview
Immune Control, Inc. is a pharmaceutical company developing compounds for treatment of multiple myeloma and other immunological diseases.
Profile
Immune Control LinkedIn Company Profile
Social Media
Immune Control Company Twitter Account
Company News
Immune Control News
Facebook
Immune Control on Facebook
YouTube
Immune Control on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Mark Strobeck
  Mark Strobeck LinkedIn Profile  Mark Strobeck Twitter Account  Mark Strobeck News  Mark Strobeck on Facebook
VP - Finance
Anne Shiflett
  Anne Shiflett LinkedIn Profile  Anne Shiflett Twitter Account  Anne Shiflett News  Anne Shiflett on Facebook


 

 

Browse more venture capital transactions:

Prev: 7/14/2005: Bradford Networks venture capital transaction
Next: 7/15/2005: Peptimmune venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We do our best to report on all VC transactions involving tech companies. VC investment data records on this site come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary